News

Indoor Biotechnologies Signs Distribution Agreement with MilliporeSigma

Indoor Biotechnologies, Inc is delighted to announce that it has entered into an agreement with Merck KGaA (Darmstadt, Germany), operating as MilliporeSigma in the US and Canada, to be a global distributor of Indoor Biotechnologies’ purified food allergens.

Under the agreement, MilliporeSigma will employ its sales, marketing, and e-commerce channels and platforms to distribute Indoor Biotechnologies’ comprehensive range of natural and recombinant food allergen analytical standards. These unique reagents have application in allergy research and diagnostics, and in the food industry. The distribution agreement covers all geographies worldwide. Indoor Biotechnologies will continue to reach customers via its own channels as well.

Indoor Biotechnologies is a leading manufacturer and supplier of highly purified allergen molecules and immunoassays for research, diagnostics, and pharmaceutical product development. Committed to quality and backed by scientific expertise, Indoor Biotechnologies’ allergen manufacturing operates under an ISO 9001:2015 certified Quality Management System. Protein identity and purity are verified by in-house mass spectrometry. Immunoreactivity is validated by IgE antibody binding. These quality systems provide consistent and high-performance allergen products.

MilliporeSigma is a leading science and technology company. In particular, MilliporeSigma offers a comprehensive portfolio of products and solutions that enable scientific research, including life science reagents and kits, laboratory and specialty chemicals, and state-of-the-art bioprocessing and workflow tools.

“With their commitment to quality and global reach, MilliporeSigma is an ideal partner for Indoor Biotechnologies. We are excited to have Indoor Biotechnologies’ biologics available through MilliporeSigma’s expansive distribution network,” commented Dr. Martin Chapman, President and CEO of Indoor Biotechnologies. “Indoor Biotechnologies’ experience in protein chemistry and robust product pipeline will be synchronized with MilliporeSigma’s network and marketing platforms. Together, we can advance our shared mission of providing high quality reagents for research and diagnostics to customers worldwide.”

Through this distribution agreement, customers will have enhanced, on-demand access to Indoor Biotechnologies’ food allergen protein portfolio through MilliporeSigma’s robust e-commerce platform, SigmaAldrich.com, regional inventory and MilliporeSigma sales representatives. Products will be stocked globally for improved availability to customers.

Transition of over 50 products from Indoor Biotechnologies’ allergen and protein portfolio to MilliporeSigma is expected to be completed in early 2021. These products will continue to be available through existing Indoor Biotechnologies channels.
The distribution agreement covers all geographies, and products will be stocked globally to improve availability to customers. Transition of over 50 products from InBio®’s allergen and protein portfolio to MilliporeSigma is expected to be completed in early 2021. These products will continue to be available through existing Indoor Biotechnologies channels.

Through the distribution agreement, InBio® and MilliporeSigma can advance the shared mission of providing high quality reagents for research and diagnostics to customers worldwide. Please stay tuned for further announcements regarding the official product launch, expected to occur in the next several months.

Recent News

04/19/2024

ivWatch prevents IV leakage events at Frimley Health

Frimley Health NHS Foundation Trust has found that 100% of IV leakage incidents were prevented by a proprietary patient monitoring system from ivWatch, which could potentially save patients the pain or discomfort of adverse IV events. The initial two-week phase of the study, which was published in the British Journal of Nursing, found that continuous

04/17/2024

U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure

Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to develop the latest generation pralidoxime chloride auto-injector as a countermeasure against organophosphate or nerve agent poisoning.

04/15/2024

Activation Capital Welcomes Dr. Jim Pannucci as its Vice President of Entrepreneurship

Activation Capital, an innovation ecosystem development organization, announced today that it has appointed Jim Pannucci, Ph.D., PMP as its Vice President of Entrepreneurship. As the new Vice President of Entrepreneurship, Dr. Pannucci will help Activation Capital continue to grow a deep talent base of life sciences entrepreneurs operating in the region and help empower them